Search

Sartorius Stedim Biotech.

Uždarymo kaina

SektoriusFinansų sektorius

178.2 2.53

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

178.2

Max

179.2

Pagrindiniai rodikliai

By Trading Economics

Pajamos

4.9M

93M

Pardavimai

4.2M

766M

P/E

Sektoriaus vid.

56.921

19.1

Pelnas, tenkantis vienai akcijai

1.25

Dividendų pajamingumas

0.41

Pelno marža

12.146

Darbuotojai

10,477

EBITDA

9.2M

240M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+29.29% upside

Dividendai

By Acuity

Dividendų pajamingumas

Sektoriaus vid.

0.41%

4.56%

Kitas uždarbis

2026-10-22

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-808M

17B

Ankstesnė atidarymo kaina

175.67

Ankstesnė uždarymo kaina

178.2

Naujienos nuotaikos

By Acuity

13%

87%

17 / 438 reitingas Finance

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-07 23:56; UTC

News

Sweetgreen shares declined in after-market trading as multiple analysts lowered price targets, with UBS and RBC both setting targets at $6.50.

2026-08-07 23:46; UTC

News

JetBlue Airways reports wider net loss and updates operating guidance. Shares are lower in after-market trading following the $121.4 million shelf registration.

2026-08-07 23:46; UTC

News

Etsy Inc shares are lower in after-market hours following its Q2 results, which showed a double beat but faced revenue challenges from divestments.

2026-08-07 23:46; UTC

News

Cogent Communications is trading lower in after-market hours amid a class action lawsuit alleging securities fraud by Pomerantz LLP and ongoing operational challenges.

2026-08-07 23:41; UTC

News

ResMed shares declined after-market despite RBC Capital raising its price target to $244 and maintaining a Sector Perform rating.

2026-08-07 23:41; UTC

News

Mitek Systems reported an 18% revenue increase in Q3, with shares advancing in after-market hours, despite earlier pulling back from a session high.

2026-08-07 23:36; UTC

News

Tripadvisor Inc announced participation in two investor conferences, enhancing engagement with investors. Shares are trading slightly higher in after-market hours.

2026-08-07 23:36; UTC

News

Shift4 Payments lowers 2026 outlook, adjusting full-year revenue guidance down by about 200 basis points. Shares are trading lower in after-market hours.

2026-08-07 23:36; UTC

News

Epam Systems shares are trading lower in after-market hours following TD Cowen's price target cut to $120, despite earlier gains in the session.

2026-08-07 23:31; UTC

News

Arcutis Biotherapeutics granted 143,500 RSUs and options to new hires. Shares are trading higher in after-market hours following the announcement.

2026-08-07 23:31; UTC

News

Figs Inc reported strong Q2 earnings but is trading lower in after-market hours as Telsey Advisory Group lowered its price target to $16.

2026-08-07 23:31; UTC

News

Ardelyx shares are higher in after-market trading as TD Cowen maintains a Buy rating and lowers the price target to $10.

2026-08-07 23:31; UTC

News

Celsius Holdings is under investigation for potential securities law violations following disappointing second-quarter results, with shares trading lower in after-market hours.

2026-08-07 23:26; UTC

News

Delta Air Lines is gaining after reporting strong second-quarter results and positive passenger traffic growth projections, with anticipated earnings of $6.63 per share.

2026-08-07 23:26; UTC

News

Five9 Inc. reported second-quarter earnings of $0.70 per share and raised full-year revenue guidance to $1.27 billion. Shares are higher in after-market trading.

2026-08-07 23:26; UTC

News

UBS raised its price target on Unity Software Inc. to $48, contributing to shares trading higher in after-market hours. Positive sentiment from tech stocks also supported this move.

2026-08-07 23:26; UTC

Event
News

Scholar Rock Holding Corp reports FDA review progress for apitegromab, with a decision expected by September 30, 2026. Shares are trading higher in after-market hours.

2026-08-07 23:26; UTC

News

Kraft Heinz Co reported second-quarter revenue of $6.26 billion, exceeding expectations. Shares rose in after-market trading amid positive sentiment and broader market strength.

2026-08-07 23:26; UTC

News

Leidos Holdings shares are lower in after-market hours after TD Cowen raised the price target to $135 while maintaining a Hold rating.

2026-08-07 23:21; UTC

News

MP Materials will participate in Canaccord Genuity's Growth Conference in August 2026. Shares are trading higher in after-market hours following the announcement.

2026-08-07 23:21; UTC

News

TD Cowen raised its price target on Akamai Technologies to $140 while maintaining a Hold rating. Shares are higher in after-market trading.

2026-08-07 23:21; UTC

Social Media
News
Event

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

2026-08-07 23:21; UTC

News

Halozyme Therapeutics reported strong Q2 earnings and raised guidance, yet shares are trading lower in after-market hours following notable weakness.

2026-08-07 23:16; UTC

News

Hawaiian Electric Industries reported Q2 revenues of $939.70 million, but adjusted EPS of $0.13 missed estimates by $0.06. Shares are trading roughly flat in after-hours.

2026-08-07 23:16; UTC

News

10X Genomics Inc shares are lower in after-market trading amid a sector decline. Citigroup raised its price target to $50 while maintaining a Neutral rating.

2026-08-07 23:11; UTC

News

Ashland Inc. is exploring a potential sale amid takeover interest, while announcing a quarterly cash dividend of $0.42 per share. Shares lower in after-market trading.

2026-08-07 23:06; UTC

News

Baker Hughes reported a stable U.S. rig count of 588, with oil rigs rising to 454 and gas rigs declining to 124. Shares were little changed in after-market trading.

2026-08-07 23:06; UTC

News

Kimberly-Clark Corp shares are lower in after-market trading, reflecting ongoing challenges with revenue and margins amid rising input costs and competition.

2026-08-07 23:06; UTC

News

Photronics Inc shares are lower in after-market trading following a class action lawsuit alleging misleading statements about its product pipeline and demand stability.

2026-08-07 23:06; UTC

News

Morgan Stanley shares are lower after-market, reflecting a slight decline. The movement follows the bank's $400 million Bitcoin purchases amid uncertain market conditions.

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

29.29% į viršų

12 mėnesių prognozė

Vidutinis 230 EUR  29.29%

Aukščiausias 260 EUR

Žemiausias 210 EUR

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

4

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

17 / 438 reitingas Finansų sektorius

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat